

Theradiag reports revenue of €6.7 million for the first half of 2023, up 6.8%

- Strong growth of 18.0% in Theranostics in H1 2023 compared with H1 2022, driven by a very good export performance (excluding the United States)
- Slight acceleration in overall growth in Q2 2023 compared with Q2 2022, driven by solid sales momentum in Theradiag two core businesses
- Cash position at June 30, 2023 above plan: €5.7m

Croissy-Beaubourg, July 17, 2023, 7.30 am CEST - THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in *in vitro* diagnostics of autoimmune diseases and theranostics, today announced its half-revenue and cash position on June 30, 2023, data that is currently being audited.

H1 2023 revenue of €6.7 million

<i>In thousands of euros</i>	Q2 2022	Q2 2023	Change	H1 2022	H1 2023	Change
Revenue	3,150	3,383	7.4%	6,264	6,688	6.8%
<i>Of which Theranostics revenue</i>	<i>1,578</i>	<i>1,727</i>	<i>9.4%</i>	<i>3,024</i>	<i>3,569</i>	<i>18.0%</i>
<i>Of which IVD revenue</i>	<i>1,572</i>	<i>1,656</i>	<i>5.3%</i>	<i>3,240</i>	<i>3,119</i>	<i>-3.7%</i>

Over the six months to June 30, 2023, Theradiag generated revenue of €6.7 million, compared with €6.3 million in the first half of 2022, representing growth of 6.8%. Growth accelerated slightly in the second quarter of 2023 thanks to strong sales performance in Theradiag two core businesses: +9.4% for Theranostics and +5.3% for In Vitro Diagnostics (IVD).

Theranostics business recorded another semester of strong growth, with sales up 18.0% to almost €3.6 million at June 30, 2023. This strong growth was driven by very good export performance and solid growth in France, offsetting the decline in sales to the US market. As a reminder, this downturn on the US market is the consequence of the implementation of the Company's new strategic plan to improve profitability.

IVD recorded a slight decline in revenue of -3.7% to around €3.1 million at the end of June 2023. Business contracted in France, compared with an exceptional first-half of 2022 figure linked to non-recurring commercial opportunities. This slowdown on the domestic market is partly offset by commercial



developments in the main European markets. Theradiag recently extended its strategic partnership with Quotient, which will support the growth trajectory of this activity.

Cash position

At 30 June 2023, Theradiag had a net cash position of €5.7 million, above the company's business plan, compared with €6.4 million at December 31, 2022.

Simon Davière, CEO of Theradiag, commented: *"During the first half 2023, Theradiag has maintained a solid sales momentum, particularly for its internally developed products, thanks to its technological lead in its two fast-growing markets. The deliberate slowdown in the United States has been offset by market share gains in new countries, mainly the major European markets. On the strength of our comfortable cash position, we intend to pursue the development and accelerate the marketing of our high-margin in-house products over the coming months."*

Christian Policard, Chairman of the Board of Directors, added: *"In addition to its strong commercial momentum, over the past few months Theradiag has been working to strengthen the collaboration with its shareholder and partner Biosynex. While synergies in purchasing are already underway, commercial synergies will need to become operational over the next six months in order to improve the performance of both companies."*

Next financial press release :

- **2023 first-half results**, on Monday 18, September 2023, before market open

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative *in vitro* diagnostic (IVD) tests for over 30 years.

Theradiag pioneered "theranostics" testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up "customized treatment" for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2022, the Company posted revenue of €12.2 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.

For more information about Theradiag, please visit our website: <https://www.theradiag.com/>

Theradiag
Simon Davière
CEO
contact@theradiag.com

NewCap
Financial Communications & Investor
Relations
Pierre Laurent / Quentin Massé
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu

NewCap
Media Relations
Arthur Rouillé
Tel.: +33 (0)1 44 71 94 94
nmerigeau@newcap.fr